Elicio Therapeutics, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Elicio Therapeutics, Inc. (ELTX) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-29.
Discontinued › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2024-03-29
- Elicio Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-12-31 was $0.00.
- Elicio Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-09-30 was $0.00.
- Elicio Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- Elicio Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-03-31 was $0.00.
- Elicio Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Elicio Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $8.02M, a 1184.78% increase from fiscal 2021.
- Elicio Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $624.00K, a 609.09% increase from fiscal 2020.
- Elicio Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2020 was $88.00K.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month as first filed | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month as first filed | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $0.00 derived: sum of 2 quarters · filed 2024-03-29 | $0.00 derived: sum of 3 quarters · filed 2024-03-29 | $0.00 10-K · filed 2024-03-29 | |||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $0.00 derived: sum of 2 quarters · filed 2023-11-13 | $0.00 10-Q · filed 2023-11-13 | $0.00 derived: sum of 4 quarters · filed 2024-03-29 | |||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $0.00 10-Q · filed 2023-08-14 | $0.00 derived: sum of 3 quarters · filed 2024-03-29 | $0.00 derived: sum of 4 quarters · filed 2024-03-29 | |||
| 2023-03-31 | $0.00 10-Q · filed 2023-05-10 | $0.00 derived: sum of 2 quarters · filed 2024-03-29 | $0.00 derived: sum of 3 quarters · filed 2024-03-29 | $8.02M derived: sum of 4 quarters · filed 2024-03-29 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $0.00 derived: sum of 2 quarters · filed 2024-03-29 | $8.02M derived: sum of 3 quarters · filed 2024-03-29 | $8.02M 10-K · filed 2024-03-29 | $0.00 10-K · filed 2023-03-17 | ||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $8.02M derived: sum of 2 quarters · filed 2023-11-13 | $8.02M 10-Q · filed 2023-11-13 | $0.00 10-Q · filed 2022-11-14 | $8.02M derived: sum of 4 quarters · filed 2023-11-13 | ||
| 2022-06-30 | $8.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $8.02M 10-Q · filed 2023-08-14 | $0.00 10-Q · filed 2022-08-15 | $8.02M derived: sum of 3 quarters · filed 2023-08-14 | $8.02M derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-10 | $0.00 derived: sum of 2 quarters · filed 2023-05-10 | $0.00 derived: sum of 3 quarters · filed 2023-05-10 | $6.00K derived: sum of 4 quarters · filed 2023-05-10 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $0.00 derived: sum of 2 quarters · filed 2023-03-17 | $6.00K derived: sum of 3 quarters · filed 2023-03-17 | $624.00K 10-K · filed 2023-03-17 | |||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $6.00K derived: sum of 2 quarters · filed 2022-11-14 | $624.00K 10-Q · filed 2022-11-14 | $127.00K derived: sum of 4 quarters · filed 2022-11-14 | |||
| 2021-06-30 | $6.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $624.00K 10-Q · filed 2022-08-15 | $127.00K derived: sum of 3 quarters · filed 2022-08-15 | $685.00K derived: sum of 4 quarters · filed 2022-08-15 | |||
| 2021-03-31 | $618.00K 10-Q · filed 2022-05-16 | $121.00K derived: sum of 2 quarters · filed 2022-05-16 | $679.00K derived: sum of 3 quarters · filed 2022-05-16 | $181.00K derived: sum of 4 quarters · filed 2022-05-16 | |||
| 2020-12-31 | -$497.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $61.00K derived: sum of 2 quarters · filed 2022-03-30 | -$437.00K derived: sum of 3 quarters · filed 2022-03-30 | $88.00K 10-K · filed 2022-03-30 | |||
| 2020-09-30 | $558.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $60.00K derived: sum of 2 quarters · filed 2021-11-12 | $585.00K 10-Q · filed 2021-11-12 | ||||
| 2020-06-30 | -$498.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $27.00K 10-Q · filed 2021-08-12 | |||||
| 2020-03-31 | $525.00K 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |